Trials / Completed
CompletedNCT05399693
Platelet Transfusion Refractoriness
Characterization of Anti-HLA I Antibodies Involved in Platelet Transfusion Refractoriness: Optimization of the Transfusion Management of Patients With Severe Thrombocytopenia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (actual)
- Sponsor
- Institut de cancérologie Strasbourg Europe · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Platelet Transfusion Refractoriness is one of the severe complications after multiple transfusions in patients with severe thrombopenia. Platelet Transfusion Refractoriness is characterized by inefficient transfusion and arise from allo-antibodies specific of platelets antigenes, mostly carried by HLA-I molecules.
Detailed description
A preliminary study has shown different isotypes of anti-HLA I in patients with Platelet Transfusion Refractoriness. Our hypothesis is that the type of anti-HLA I antibodies (recognised epitope, quantity, isotype) should establish predictive and diagnostic criteria for Platelet Transfusion Refractoriness.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | platelet transfusion | platelet transfusion realised for Hematopoietic stem cells graft or for acute leukemia |
Timeline
- Start date
- 2022-02-02
- Primary completion
- 2023-08-08
- Completion
- 2023-08-08
- First posted
- 2022-06-01
- Last updated
- 2026-01-05
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05399693. Inclusion in this directory is not an endorsement.